Jpmorgan Chase & CO Protagonist Therapeutics, Inc Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 502,985 shares of PTGX stock, worth $20.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

502,985

Previous 376,588 33.56%

Holding current value

$20.6 Million

Previous $13 Million 73.24%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$33.72 - $47.33 $4.26 Million - $5.98 Million	126,397 Added 33.56%	502,985 $22.6 Million
Q2 2024 Aug 12, 2024	BUY	$24.66 - $34.8 $3.43 Million - $4.84 Million	139,148 Added 58.6%	376,588 $13 Million
Q1 2024 May 10, 2024	SELL	$21.79 - $32.15 $3.78 Million - $5.58 Million	-173,606 Reduced 42.24%	237,440 $6.87 Million
Q4 2023 Feb 12, 2024	BUY	$14.05 - $23.44 $2.51 Million - $4.19 Million	178,756 Added 76.95%	411,046 $9.43 Million
Q3 2023 Nov 14, 2023	SELL	$16.68 - $23.66 $540,715 - $766,986	-32,417 Reduced 12.25%	232,290 $3.87 Million
Q2 2023 Aug 11, 2023	BUY	$18.02 - $29.36 $2.86 Million - $4.66 Million	158,574 Added 149.41%	264,707 $7.31 Million
Q1 2023 May 18, 2023	BUY	$10.78 - $25.38 $384,231 - $904,619	35,643 Added 50.56%	106,133 $2.44 Million
Q1 2023 May 11, 2023	SELL	$10.78 - $25.38 $2.51 Million - $5.91 Million	-232,672 Reduced 76.75%	70,490 $1.62 Million
Q4 2022 Feb 13, 2023	BUY	$7.36 - $11.17 $939,158 - $1.43 Million	127,603 Added 72.68%	303,162 $3.31 Million
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $432,803 - $644,799	55,064 Added 45.7%	175,559 $1.48 Million
Q2 2022 Aug 11, 2022	BUY	$7.06 - $25.52 $362,262 - $1.31 Million	51,312 Added 74.17%	120,495 $954,000
Q1 2022 May 11, 2022	SELL	$23.34 - $36.08 $8.57 Million - $13.3 Million	-367,270 Reduced 84.15%	69,183 $1.64 Million
Q4 2021 Feb 10, 2022	BUY	$17.63 - $37.1 $136,773 - $287,821	7,758 Added 1.81%	436,453 $14.9 Million
Q3 2021 Nov 12, 2021	BUY	$12.95 - $49.69 $5.55 Million - $21.3 Million	428,695 New	428,695 $7.6 Million

Others Institutions Holding PTGX

# of Institutions

246

Shares Held

56.5M

Call Options Held

76.3K

Put Options Held

114K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.01B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Protagonist Therapeutics, Inc Transaction History